A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

NCT01680991 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

Interventions

DRUG: Obinutuzumab

Sponsor

Hoffmann-La Roche